Physician profile
Elliot Borgen
NPI 1528017852
$4,586.13
in general payments reported to CMS, 2019-2025
22 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $418 · 2021: $182 · 2022: $518 · 2023: $462 · 2024: $291 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,276 · Food and Beverage: $1,230 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,275.80 |
| Food and Beverage | $1,229.78 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,472.27 | 2020-2025 | Triclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $728.22 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $378.44 | 2019-2024 | |
| Medtronic, INC. | $317.74 | 2022-2025 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals Lp | $230.06 | 2019-2024 | |
| Edwards Lifesciences Corporation | $228.79 | 2019-2025 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $196.32 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $187.22 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $183.27 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $175.96 | 2024-2025 | Verquvo |
| Pfizer INC. | $138.20 | 2019-2024 | |
| Cook Medical LLC | $77.13 | 2021-2025 | Zenith Alpha |
| Medicomp INC | $43.75 | 2025 | Telepatch Cardiac Monitor |
| Irhythm Technologies, INC. | $38.45 | 2019 | |
| Acist Medical Systems, INC. | $29.20 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $29.14 | 2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.95 | 2021 | |
| Boston Scientific Corporation | $26.66 | 2023 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $22.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.52 | 2024 | Camzyos |
| Astellas Pharma US INC | $18.75 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $16.22 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Borgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.